I agree that the new board is non performing better then the old management and they have failed to meet milestones and looked like a bunch of rookies withtheir capital raising efforts. But I don't think they are performing much worse than the old board!
IMO revenue is not really a key here, it's getting the backing of KOL's, clinical data etc and then the revenue will follow.
I look with interest to the next Appendix 4C to see if the cash burn rate has slowed as they keep saying it has. Regardless, to continue to push forward with the company strategy another capital raising will be needed by at the latest August / September this year to ensure they can sign the full year accounts off as a going concern and without avoid an adverse audit opinion.
IMO the only thing that's likely to drive the share in the short term is a binding agreement with a high profile partner or similar.
ISN Price at posting:
8.0¢ Sentiment: Hold Disclosure: Held
